$IBRX On Friday, Patrick Soon-Shiong went on the Sean Spicer show and, in one quiet sentence, described the biggest opening this drug has ever had. The UAE, he said, wants to take ANKTIVA "to the next level, which is lymphopenia," for "all cancer types." Not one cancer. The failing immune system itself. If you follow this company, you felt what happened next. The boards lit up. Stocktwits, X, Reddit, everywhere we gather, one word started bouncing around: lymphopenia, this is going to be massive. They may well be right. But here is what struck us. In all that noise, we have not seen a single person actually stop and put a number on it. We seem to split into two camps. Those who are certain it is about to be enormous, and those who have never heard the word and quietly have no idea what it even means. Both are guessing, because nobody has done the arithmetic. So we did, the way we did it for Germany a few days ago, and for the Gulf before that. We took the sentence apart, counted the patients, put a price on it, and left every dial in your hands. Nothing is signed. This is not a prediction and not advice, just pure curiosity about a question the whole board is arguing over. What fell out of the math surprised us. Build it with us below. WHAT HE ACTUALLY SAID In his words, the UAE told him: "we want you to start here, because we want to then take you to the next level, which is lymphopenia." In their eyes, he said, the drug works "for all cancer types." He was careful, over and over, to say this is the UAE, not the FDA. But the direction was unmistakable. Bladder and lung were the start. Lymphopenia, treated with a simple injection under the skin in anyone whose immune cells have fallen too low, is where they want to go, and he says they already have the data. Separately, talking about the trials he is chasing, he named one more frontier: sepsis. WHY THE UAE, AND WHY IT GOES FURTHER THAN THE FDA To see why this is not idle talk, look at what the UAE has already done. Twice. For bladder cancer, the American FDA cleared ANKTIVA for one form of the disease. The UAE went a step further and added a second group the FDA still has not cleared, and will not even rule on until January. Further than the FDA. And further than Saudi Arabia, which on bladder matched the FDA exactly. For lung cancer, the FDA has cleared nothing at all. The Gulf approved it anyway, Saudi Arabia first and then the UAE, on the trial data alone. That is the pattern. The UAE does not wait for the FDA, and it does not stop where the FDA stops. Nothing here is approved yet, and it may never be. But if it does move on lymphopenia the way it moved on bladder and lung, the question becomes not just whether it approves, but how far past the FDA it would go. AMERICA ALREADY DREW THE FIRST LINE And here is what makes it concrete. There is a program in the United States right now that already lets doctors give ANKTIVA to cancer patients whose lymphocyte counts have collapsed. It is not a full approval, it does not endorse the benefit, and it earns the company almost nothing, because these programs are provided at cost. But it matters for a simpler reason. The American system has already accepted, in practice, that these are patients this drug is meant to reach. So the floor here is that group, cancer patients with wrecked immune systems, and the ceiling is the "all cancer types" the UAE described. Sepsis, the seriously ill beyond cancer, is a separate program we will size on its own. We sized both. THE SIZE OF YOUR ARMY Think of your immune system as a standing army, and your lymphocytes, chiefly the T cells and natural killer cells, as its soldiers. Lymphopenia is simply that army falling below fighting strength. And it is not only a cancer problem. The ranks fall in cancer patients on chemotherapy or radiation, and they fall just as hard in sepsis, when an infection overwhelms the body. When too many soldiers are gone, the body can no longer hold the line and infection walks straight in. Those two sick groups, cancer and sepsis, are the ones we will count, and nothing else. There is even a headcount. It is called the ALC, and it sits on almost every blood test ever run. A large study in a leading American journal found that as that headcount falls toward 1,000, all-cause risk of dying roughly doubles, and for specific causes like cancer, heart disease and infection the risk runs several times higher. It is an association, not proof that the thin ranks themselves do the damage. But the pattern is hard to miss: the smaller the army, the worse the odds. And that is the whole point of the drug. ANKTIVA's entire job is to call up reinforcements and rebuild the count. So the thesis fits in one line: the size of your immune army predicts your survival, and this drug rebuilds the army. NOW LET'S BUILD THE NUMBER So how big is the door, if it opens? Nobody can hand you one number, because it turns on the one thing nobody has defined yet: how wide the label is. So we will not hand you a number. We will build it in front of you, in four steps, and hand you every dial. Turn any one you like. STEP ONE: COUNT THE FALLEN Start with the cancer army, because that is the part we can actually count. - The Gulf sees about 42,500 new cancers a year - Of those patients, roughly 65 percent are put on chemotherapy or radiation, the treatments that thin the ranks - Of those, somewhere between half and two thirds watch their immune army fall below strength Multiply it through and you land at about 15,000 people a year, in the Gulf alone, whose defences this drug is built to rebuild. That is the grounded floor of the pool, and every number in it comes from published cancer data. STEP TWO: THE PRICE NOBODY WILL PRINT Now what a course costs, and this is the softest number in the whole post. There is no approved price for this use, because there is no approved course for it yet: PSS described an injection under the skin, and nobody has published a dose, a schedule, or a price. So we borrow one. In America, the approved bladder course runs about 322,000 dollars. Outside America, drugs like this sell for something like 40 to 70 percent of the US price, so we will use about 175,000 dollars as a stand-in. Too high, too low? Change it. The math does not care. STEP THREE: HOW MANY ACTUALLY GET IT No new drug reaches everyone at once. It reaches a sliver first, then grows as doctors and payers come on board. So turn that dial: 5 in 100, 15 in 100, 40 in 100. STEP FOUR: NOW MULTIPLY Put the three together, 15,000 people, about 175,000 dollars a course, and the share who actually get it: - 15,000 x 175,000 x 5 percent = about 130 million a year. - 15,000 x 175,000 x 15 percent = about 400 million. - 15,000 x 175,000 x 40 percent = about a billion. Now hold that against the company as it stands today: ImmunityBio sold about 113 million dollars of everything, in all of last year. So the middle of this, on cancer alone, in one region, is already several times the entire company. And cancer is only the first of the two sick groups this drug is built for. A SECOND PROGRAM, AND A BIGGER ONE Everything to here is the cancer conversation, the one the UAE described. But the same idea, rebuilding a collapsed immune army, applies to sepsis, and that is a separate program the company is already running, not part of the UAE lymphopenia talks. Its sepsis work has an early-stage protocol already submitted to the FDA and a Phase 3 planned across Saudi Arabia, the United States and the UAE. It is earlier and less certain than the cancer work: where cancer has real survival data behind it, sepsis has only an early trial and a promising idea so far. But the pool is far larger. In the Gulf, the number of sepsis patients whose immune army falls is not 15,000. It is on the order of 90,000 a year, and that count is a rough estimate. It is the same drug, at the same price per dose. The difference is that sepsis is an emergency, not a years-long course, so a patient gets a short burst rather than the full cancer regimen, call it about 60,000 dollars a head. - 90,000 x 60,000 x 5 percent = about 270 million a year. - 90,000 x 60,000 x 15 percent = about 810 million. - 90,000 x 60,000 x 40 percent = about 2.2 billion. So the second door, if it opens, is bigger than the first. Keep them apart in your head, because they are apart in reality. At a realistic uptake, cancer lymphopenia, the one the UAE is discussing now, is worth roughly 400 million to a billion a year; and sepsis, still a planned trial, roughly 800 million to over two billion. Two separate doors, the same drug, one region. Neither is signed. AND THIS IS ON TOP OF EVERYTHING ELSE Hold on to one thing: none of this replaces what the drug already has. It adds to it. What ANKTIVA is already cleared to sell, in America today, in Europe for bladder, and in the Gulf for bladder and lung, is a real, approved business worth a few hundred million dollars a year as it ramps. Everything we just built, for lymphopenia and for sepsis, sits entirely on top of that. If these doors open, they do not add another engine. They dwarf the ones already running. The full tally is at the end. WHERE THE MONEY REALLY SITS Whichever door you are looking at, the money does not arrive as one lump, and where it sits is not what you would guess. Take the cancer middle case, about 400 million dollars a year. More than half of it, call it 220 to 260 million, is the Gulf state buying this for its own citizens, the same governments already spending well over a billion a year flying their patients abroad for care they could soon give at home. Another hundred million or so runs through the private and employer insurers that cover the expatriate majority, where cancer coverage is real but uneven. The rest, a few tens of millions, is patients sponsored in from neighbouring countries and a small tail of the wealthy who travel for what they cannot get at home. The sepsis program, if it lands, flows through the very same channels. Nothing here leans on Dubai's wellness tourism, where cancer barely registers. The full split, region by region and door by door, is in the branded table attached to this post. WHY A GOVERNMENT WOULD WRITE THAT CHECK You might reasonably ask why any government would spend this kind of money. PSS never quite spells it out. But put on a detective's hat and it takes about a minute, because he left both clues lying on the same show. Clue one: asked about the economics of people living longer, he reached for a paper in Nature Aging that puts a dollar figure on healthy years of life. Add a single year to average life expectancy, it found, and in a country the size of the United States the value runs into the tens of trillions of dollars, through a healthier, more productive population. Clue two, a few minutes earlier: he was describing the Gulf, and he made a point of their population being young, average age around thirty, and of how keeping it healthy and productive for the decades ahead is exactly what they are spending their sovereign wealth on. Lay the two side by side, and the answer is obvious. To a young, rich country doing that math, a drug that rebuilds the immune system is not a line on a health budget. It is an investment in its workforce. In its future. In the long survival of a small nation betting everything on its own people. That is why the biggest cheque here is a state cheque. THE VERSION WE THREW OUT That same logic points at a much bigger version, and it is worth being honest about why we still left it out of the numbers. Imagine treating people who are not sick at all, healthy and feeling fine, just carrying a slightly low count, on the theory that rebuilding their immune system buys them healthy years. Do that across a young, wealthy population and you can conjure single-digit billions in the Gulf, tens of billions once you add America. This is the longevity frontier PSS keeps pointing at, and the economic case for it is real. But it is a thesis, not a market. No health system reimburses an expensive injection for people who feel well today, and the proof that it extends their lives does not yet exist. So we keep it out of the cash math, as the prize beyond the prize, not a number anyone collects yet. Every figure above is sick patients, real reimbursement, real data. THE WHOLE BOARD It is easy to lose the numbers along the way, so here is the whole board laid out plainly. Only one of these is actually in the bank yet: America, where ANKTIVA is running near a 200 million dollar annual pace. Two more doors are open but barely earning, Europe, which we sized at around 120 million a year, and the Gulf's bladder and lung approvals, sized between 140 and 300 million. Approved and real, but the money has only just started to flow. And the two doors we just built, both still unsigned, both in the Gulf alone: cancer lymphopenia, the one the UAE is discussing now, worth roughly 400 million to a billion dollars a year; and sepsis, a separate planned program, worth roughly 800 million to over 2 billion. Neither indication exists yet. Yet either one, at a realistic uptake, already beats everything the drug sells on the whole planet today. And even this is not the whole board. Back in February, ImmunityBio laid out a formal three-year plan: more than a dozen cancers and over twenty trials, from pancreatic and colorectal to brain, breast and lymphoma, plus a bigger bladder filing already headed to the FDA. Most are earlier and less certain than what we sized here. But we put numbers on only a corner of that plan. Every other door is upside, and not one of them is in a single figure above. And none of it counts the developing world, the millions who could never pay for this themselves but whom a global health fund could pay to reach, which is exactly why ImmunityBio just made the former head of the World Bank its vice chairman for global access. NONE OF IT IS SIGNED One line matters more than every number above it: none of this is signed. The UAE has not approved anything for lymphopenia. PSS says he is in conversations and has the data. Conversations are not a purchase order. Everything here is the size of the prize, not a promise that anyone collects it. Every figure is a dial you can turn, and we picked what we could defend and showed our work. The receipts, every number and its source, are in the reply below. So here is the whole thing in one line. There is a number on your blood test that quietly predicts how long you live. There is a drug that can move it. And there is a government that keeps approving what the FDA will not. Put those three together and the prize, across two doors in one small region, runs from a few hundred million to many times over this entire company, before America is even in the room. None of it is signed. All of it is now on the table. And you are no longer in the dark about how big the table is.

Wowza @WearForbidden

Anyone who opposes remigration is a traitor